Skip to content

Citius Oncology, Inc.: 10-Q filed 2026-05-15

What Citius Oncology, Inc. reported in its quarterly report filed 2026-05-15 (fiscal Q2 2026): 40 published measures, 105 facts as tagged in accession 0001213900-26-057841.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-15
Fiscal period
fiscal Q2 2026
Accession
0001213900-26-057841 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Oncology, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-31100,699,168USD
At 2025-09-30100,942,881USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-3165,430,399USD
At 2025-09-3056,076,650USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-3135,268,769USD
At 2025-12-3158,413,701USD
At 2025-09-3044,866,231USD
At 2025-03-3135,642,632USD
At 2024-12-3141,289,612USD
At 2024-09-3046,140,339USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-03-312,632,634USD
At 2025-09-303,924,908USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-26,609,695USD90
2025-10-01 to 2026-03-31-32,143,764USD182
2025-10-01 to 2025-12-31-5,534,069USD92
2025-01-01 to 2025-03-31-7,735,552USD90
2024-10-01 to 2025-03-31-14,394,757USD182
2024-10-01 to 2024-12-31-6,659,205USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-10-01 to 2026-03-31-11,186,564USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,667,298USD90
2025-10-01 to 2026-03-315,611,409USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-10-01 to 2026-03-3114,894,290USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-10-01 to 2026-03-31-5,000,000USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-96,183,720USD
At 2025-09-30-64,039,956USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-31100,027,204shares90
2025-10-01 to 2026-03-3193,657,757shares182
2025-01-01 to 2025-03-3171,552,402shares90
2024-10-01 to 2025-03-3171,552,402shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-31100,027,204shares90
2025-10-01 to 2026-03-3193,657,757shares182
2025-01-01 to 2025-03-3171,552,402shares90
2024-10-01 to 2025-03-3171,552,402shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.27USD/shares90
2025-10-01 to 2026-03-31-0.34USD/shares182
2025-01-01 to 2025-03-31-0.11USD/shares90
2024-10-01 to 2025-03-31-0.2USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.27USD/shares90
2025-10-01 to 2026-03-31-0.34USD/shares182
2025-01-01 to 2025-03-31-0.11USD/shares90
2024-10-01 to 2025-03-31-0.2USD/shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-231,210USD90
2025-10-01 to 2026-03-3133,030USD182
2025-01-01 to 2025-03-31264,240USD90
2024-10-01 to 2025-03-31528,480USD182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-03-313,526,710USD90
2025-10-01 to 2026-03-317,482,760USD182
2025-01-01 to 2025-03-312,088,572USD90
2024-10-01 to 2025-03-313,897,050USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-28,613,595USD90
2025-10-01 to 2026-03-31-33,865,871USD182
2025-01-01 to 2025-03-31-7,471,312USD90
2024-10-01 to 2025-03-31-13,866,277USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-3129,423,666USD
At 2025-09-3027,542,881USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-3158,812,298USD
At 2025-09-3049,491,579USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-03-318,883,239USD
At 2025-09-3013,234,684USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-03-311,079,055USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-3129,952,015USD90
2025-10-01 to 2026-03-3138,359,194USD182
2025-01-01 to 2025-03-317,471,312USD90
2024-10-01 to 2025-03-3113,866,277USD182

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2026-03-3122,659,590USD
At 2025-09-3022,286,693USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,338,420USD90
2025-10-01 to 2026-03-314,493,323USD182

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2026-01-01 to 2026-03-31328,878USD90
2025-10-01 to 2026-03-311,118,086USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,079,354USD90
2025-10-01 to 2026-03-312,097,706USD182
2025-01-01 to 2025-03-313,139,413USD90
2024-10-01 to 2025-03-314,403,921USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-3192,981,204shares
At 2025-09-3083,513,442shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-03-312,632,634USD
At 2025-09-303,924,908USD
At 2025-03-31112USD
At 2024-09-30112USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-31131,443,191USD
At 2025-09-30108,897,836USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-03-3124,057,573USD
At 2025-09-304,093,124USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2026-03-312,817,990USD
At 2025-09-302,784,960USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-26,840,905USD90
2025-10-01 to 2026-03-31-32,110,734USD182
2025-01-01 to 2025-03-31-7,471,312USD90
2024-10-01 to 2025-03-31-13,866,277USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-3123,625,639USD90
2025-10-01 to 2026-03-3126,484,978USD182
2025-01-01 to 2025-03-312,243,327USD90
2024-10-01 to 2025-03-315,565,306USD182

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-01-01 to 2026-03-3133,031USD90
2025-10-01 to 2026-03-3178,872USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,772,690USD90
2025-10-01 to 2026-03-311,755,137USD182

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2025-10-01 to 2026-03-3133,030USD182
2024-10-01 to 2025-03-31528,480USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-10-01 to 2026-03-3114,460USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-10-01 to 2026-03-3115,063,542USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2026-03-311,079,055USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2026-03-31372,897USD182
2024-10-01 to 2025-03-317,070,487USD182

Inspect the source

Entity
Citius Oncology, Inc. / CIK 0001851484
Captured
2026-09-21T17:32:34.031Z
SEC response SHA-256
1e8c39a029a9529c1971ba7b07551c1ef4dd6de443d807231887851f2cef037a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001851484.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))